Wells Fargo’s ALX Oncology ALXO Stock Holding History

Wells Fargo’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$11.3K	–	7665
2022 Q4	$11.3K	Buy	+1,000	New	+$11.2K	﹤0.01%	5500
2022 Q3	–	Sell	-1,000	Closed	-$8K	–	6610
2022 Q2	$8K	Buy	+1,000	New	+$10.9K	﹤0.01%	5831

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wells Fargo's ALXO Position: Q3 2025 in Review

Wells Fargo sold out of ALX Oncology (ALXO) in Q3 2025, closing a stake of 447 shares — an estimated $186 sold.

Wells Fargo first reported a position in ALXO in Q3 2020 and held it in 20 quarters. The position peaked at $1.16M in Q4 2020. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

Wells Fargo reported no remaining ALX Oncology position as of Q3 2025 after selling out during the quarter.
Wells Fargo sold 447 ALX Oncology shares in Q3 2025, an estimated $186.
Wells Fargo first reported a position in ALX Oncology in Q3 2020 and held it in 20 quarters.
Wells Fargo's ALX Oncology position peaked at $1.16M in Q4 2020.
61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.